ALKEM2024-10-012024-12-31 ALKEM2024-10-012024-12-31 ALKEM2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member ALKEM2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member ALKEM2024-12-31 ALKEM2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ALKEM2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member ALKEM2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss02Member ALKEM2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member ALKEM2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 539523 ALKEM NOTLISTED Alkem Laboratories Limited Equity 2024-04-01 2025-03-31 2025-02-07 2025-01-28 INR Millions Third quarter 11:00:00 13:40:00 2025-02-07 2025-02-07 Not applicable Single segment The Company is exclusively engaged in pharmaceutical business 2024-10-01 2024-12-31 Unaudited Standalone 22868300000.00 1691800000.00 24560100000.00 6931300000.00 1209000000.00 -881500000.00 4184800000.00 210000000.00 676100000.00 4846400000.00 17176100000.00 7384000000.00 0.00 7384000000.00 1198800000.00 -577100000.00 621700000.00 0.00 6762300000.00 720700000.00 251800000.00 468900000.00 0.00 7231200000.00 -24900000.00 7206300000.00 0.00 0.00 239100000.00 2 56.56 56.56 3.92 3.92 60.48 60.48 1.The above unaudited SFR are prepared as per IndAS prescribed under sec. 133 of the Companies Act, 2013 and are in compliance with the disclosure requirements of Reg. 33 of the SEBI LODR. 2.The above unaudited SFR of the Co. were recommended by the Audit Committee on 06.02.2025 and approved by the BOD at its meeting held on 07.02.2025. Auditors have issued an unmodified review report on the same. 3.The BOD at its meeting held on 10.12.2024 approved to transfer its Generic Business Undertaking to Alkem Wellness Limited, a WOS of the Company as a going concern on a slump sale basis. Consequently the proposed transfer of Generic Business has been disclosed as discontinued operations in accordance with Ind AS 105 Non - current Assets Held for Sale and Discontinued Operations . The previous period have been restated to give effect to the presentation requirement of Ind AS 105. The Co. is currently in process of executing the BTA. Key financial information of Discontinued Operations has been stated in the PDF file. (Due to characters size constraints) 4.The comparative financial information of the Co for quarter and nine months ended 31.12.2023 and for YE 31.03.2024 prepared in accordance with Ind AS included in this statement have been reviewed and audited respectively by the predecessor auditor. The reports of the predecessor auditor on these comparative financial information are dated 09.02.2024 and 29.05.2024. These previously issued financial information have been adjusted to comply with Ind AS 105 “Non-current Assets Held for Sale and Discontinued Operations” and included in this Statement as comparative financial information. The adjustments made to the previously issued financial information to comply with Ind AS have been reviewed and audited by existing auditors, as applicable. 5.Exceptional item for the YE 31.03.2024 includes impairment loss of Rs 415.6 Mn towards its plant located at Indore. Subsequently, in the previous QE 30.09.2024, the Co as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently, related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale. Also, in QE 31.12.2023, a cyber security incident which compromised business email IDs of certain employees at one of the subsidiaries resulted in a fraudulent transfer of funds of approx Rs 513.1 Mn which was disclosed as exceptional item for the quarter and nine months ended 31.12.2023. In the subsequent QE 31.03.2024, the Co. recovered Rs 290.4 Mn out of the above amt and hence amt of Rs 222.7 Mn was disclosed under exceptional item for YE 31.03.2024. 6.The BOD at its meeting held on 07.02.2025 have declared an interim dividend of Rs 37/- per equity share for FY 31.03.2025. 7.The Co. operates in one reportable business segment i.e. Pharmaceuticals , accordingly no separate disclosure of segment information has been made. Single segment 2024-04-01 2024-12-31 Unaudited Standalone 67685000000.00 3954700000.00 71639700000.00 19445100000.00 3043700000.00 -1305300000.00 12293300000.00 592000000.00 1919700000.00 15614100000.00 51602600000.00 20037100000.00 0.00 20037100000.00 3133800000.00 -1735100000.00 1398700000.00 0.00 18638400000.00 2153700000.00 752600000.00 1401100000.00 0.00 20039500000.00 -74700000.00 19964800000.00 0.00 0.00 239100000.00 2 155.89 155.89 11.71 11.71 167.60 167.60 Other Expenses 4846400000.00 Other Expenses 15614100000.00 Remeasurements of defined benefit plans -39900000.00 Remeasurements of defined benefit plans - discontinued operations 1600000.00 Remeasurements of defined benefit plans -119500000.00 Remeasurements of defined benefit plans - discontinued operations 4700000.00 -38300000.00 -114800000.00 -13400000.00 -40100000.00 Foreign currency translation difference of foreign operations 0.00 Foreign currency translation difference of foreign operations 0.00 0.00 0.00 0.00 0.00